First Procedures Performed With Millipede's 50-mm Transcatheter Annuloplasty Ring
July 24, 2017—Millipede, Inc. announced the successful implantation of its new 50-mm Iris annuloplasty ring with a transfemoral, transseptal delivery catheter in a patient with functional mitral regurgitation (MR).
According to the company, the Millipede Iris is a complete and adjustable ring that allows the physician to size and adjust for the patient's anatomy and valve geometry. The Iris ring is also repositionable and retrievable during the implantation procedure adding an additional dimension of safety to the procedure for physicians and their patients.
Jason Rogers, MD, Professor of Cardiovascular Medicine at UC Davis in Davis, California, commented in the company's announcement, "The new 50-mm diameter Iris implant allows easier placement and more robust annular reduction of the large-diameter mitral annuli that are typically seen in severe functional MR. This rapid iteration by the Millipede team of the device and delivery system has markedly improved ease of use and expands the treatable patient population."
As part of Millipede's clinical experience, a MitraClip (Abbott Vascular) was used successfully after a previously placed Millipede Iris—at 18 months postimplantation. The patient was clinically stable for 15 months after the Millipede therapy and presented again 3 months ago with a torn chord caused by progressive degenerative disease. A single MitraClip, placed inside the Millipede Iris, resolved the chordal issue. Dr. Rogers noted, "Compatibility with existing transcatheter therapies, for both degenerative MR and functional MR patients, is an important feature of the Millipede Iris."
In May, the company announced that the first clinical use of the transcatheter Iris complete annuloplasty ring was performed at the Italian Hospital in Asunción, Paraguay. The procedure was conducted by Dr. Rogers and Prof. Eberhard Grube, MD.